IFNA2 and COVID-19: In a retrospective single-center study involving 94 confirmed COVID-19 patients, therapeutic regimens of IFN-α + LPV/r and IFN-α + LPV/r + RBV were found to be beneficial for reducing IL-6 and C-reactive protein levels in COVID-19 patients [151].